This clinical trial is focused on studying the long-term safety of a treatment called GSK3511294, also known as Depemokimab, for individuals with severe asthma that has a specific characteristic known as an eosinophilic phenotype. Asthma is a condition that affects the airways in the lungs, making it difficult to breathe. The eosinophilic phenotype refers to a type of asthma where there is a higher number of a certain type of white blood cell called eosinophils, which can cause inflammation and worsen asthma symptoms.
The purpose of this study is to observe how safe Depemokimab is when used over a long period. Participants in this study will receive Depemokimab as a solution for injection under the skin every 26 weeks, in addition to their existing asthma treatments. The study will last for about 12 months, during which the participants’ health will be monitored to identify any side effects or reactions to the treatment.
This study is an open-label extension, meaning that all participants will know they are receiving Depemokimab, and it is designed for those who have already completed previous related studies. The study aims to gather information on any adverse events, which are unexpected medical problems, and to check for any immune responses to the drug, such as the development of antibodies against it. Participants’ asthma control and lung function will also be assessed at various points during the study to understand the treatment’s impact on their condition.
Czechia 
France 
Germany 
Hungary 
Italy 
Poland 
Spain 
